Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer.

Abstract

BACKGROUND:

Some studies have shown that high body mass index (BMI) is associated with inferior outcome after adjuvant therapy with anastrozole in breast cancer patients. We aimed to investigate predictive effect of BMI on clinical response to neoadjuvant therapy with exemestane in postmenopausal patients with primary breast cancer.

PATIENTS AND METHODS:

The study group consisted of 109 patients from the JFMC 34-0601 neoadjuvant endocrine therapy trial. Patients were categorized into three groups according to BMI: low (BMI < 22 kg/m(2)), intermediate (22 ≤ BMI < 25 kg/m(2)) and high (BMI ≥ 25 kg/m(2)). Statistical analyses were performed to explore the predictive effect of BMI on clinical response.

RESULTS:

Higher BMI correlated with positive progesterone receptor status (p < 0.01) and low Ki-67 index (p = 0.03). Objective response rates (ORR) were 21.7% in low BMI, 56.0% in intermediate BMI and 60.6% in high BMI, respectively (p = 0.01). In a multivariate analysis, low BMI was an independent negative predictor of clinical response.

CONCLUSION:

Low BMI was associated with a decreased ORR to neoadjuvant endocrine therapy with exemestane. Our results may suggest that the predictive effect of BMI varies according to the type of aromatase inhibitor and objective outcome.

• Authors: Masahiro Takada, Shigehira Saji, Norikazu Masuda, Katsumasa Kuroi, Nobuaki Sato, Hiroyuki Takei, Yutaka Yamamoto, Shinji Ohno, Hiroko Yamashita, Kazufumi Hisamatsu, Kenjiro Aogi, Hiroji Iwata, Takayuki Ueno, Hironobu Sasano, Masakazu Toi
• Journal: Breast (Edinburgh, Scotland) (Breast) Vol. 21 Issue 1 Pg. 40-5 (Feb 2012) ISSN: 1532-3080 [Electronic] Netherlands
• PMID: 21855342 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2011 Elsevier Ltd. All rights reserved.

Chemical References

• Androstadienes
• Aromatase Inhibitors
• exemestane

Topics

• Aged
• Androstadienes (therapeutic use)
• Aromatase Inhibitors (therapeutic use)
• Body Mass Index
• Breast Neoplasms (drug therapy)
• Chemotherapy, Adjuvant
• Female
• Humans
• Middle Aged
• Neoadjuvant Therapy
• Postmenopause
• Preoperative Care
• Treatment Outcome